Astellas Halts Development of Stroke Prevention Drug Darexaban

Astellas Pharma Inc. (4503) will discontinue global development of darexaban maleate, a drug for preventing strokes and blood clots, because competition has increased in the sector and it can’t find a partner to develop and commercialize the drug.

The discontinuation won’t affect the Japanese drugmaker’s earnings forecast for this fiscal year, according to a statement on Astellas’ website today.

To contact the reporter on this story: Go Onomitsu in Tokyo at

To contact the editor responsible for this story: Gearoid Reidy at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.